Tumor-specific shared antigenic peptides recognized by human T cells. - Wikidata - wikimedia - TriplyDB

Tumor-specific shared antigenic peptides recognized by human T cells.

Tumor-specific shared antigenic peptides recognized by human T cells.

http://www.wikidata.org/entity/Q35005926

about

Immunomic analysis of human sarcoma Mimotopes for alloreactive and conventional T cells in a peptide-MHC display library Structural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restriction Proline substitution independently enhances H-2D(b) complex stabilization and TCR recognition of melanoma-associated peptides DNA vaccine for cancer immunotherapy An efficient strategy to induce and maintain in vitro human T cells specific for autologous non-small cell lung carcinoma Murine leukemia RL male 1 and sarcoma Meth A antigens recognized by cytotoxic T lymphocytes (CTL).A novel, rapid strategy to form dendritomas from human dendritic cells and hepatocellular carcinoma cell line HCCLM3 cells using mature dendritic cells derived from human peripheral blood CD14+ monocytes within 48 hours of in vitro culture.An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention Use of baculovirus MHC/peptide display libraries to characterize T-cell receptor ligands.High-resolution analysis of HLA class I alterations in colorectal cancer.Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research.Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer.DNA vaccines: developing new strategies against cancer.Vaccine prevention of cancer: can endogenous antigens be targeted?Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes.Association of MAGE A1-6 Expression with Lung Cancer Progression.Identification of cancer/testis-antigen genes by massively parallel signature sequencing.Promoter hypomethylation and reactivation of MAGE-A1 and MAGE-A3 genes in colorectal cancer cell lines and cancer tissues.Evolutionary history of the cancer immunity antigen MAGE gene family.CD8(+) T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect.Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cells The stable traits of melanoma genetics: an alternate approach to target discovery Induction of protective anti-CTL epitope responses against HER-2-positive breast cancer based on multivalent T7 phage nanoparticles.Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy Epigenetic hierarchy within the MAGEA1 cancer-germline gene: promoter DNA methylation dictates local histone modifications.In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.In vitro and ex vivo evaluation of a multi-epitope heparinase vaccine for various malignancies.Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP ALK a novel lymphoma-associated tumor antigen for vaccination strategies.Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer Options for T-cell based therapies.Improving Multi-Epitope Long Peptide Vaccine Potency by Using a Strategy that Enhances CD4+ T Help in BALB/c Mice.Targeting cytotoxic T lymphocytes for cancer immunotherapy.Challenges and future perspectives of T cell immunotherapy in cancer Gene transfer approaches in cancer immunotherapy.An innately interesting decade of research in immunology.Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors.

P2860

Q24554211-84417C28-9B44-439E-B0F6-8AE159138EAF Q24804498-9B176A89-79F6-4529-8F41-CBBDB83C7761 Q27676136-CCCB1542-C5F9-4DDB-B095-F64B679F2F3F Q27685375-95263D99-BEB5-46B0-9880-A967AC8F38AA Q28080919-71F66543-FF9F-4467-88E4-F85D4ED5C68E Q28749871-F48AF4A1-3EED-4337-9EC8-AEEB67BF2183 Q31023643-A7AF88BA-2A12-438C-8839-DED0E96B78DB Q33208820-2D95CF1B-1DDF-4E47-91C2-314D808ABA2A Q33229377-D7DEE5D2-A115-44EF-9842-B75E9EEACAA1 Q33240318-A7C15E32-3E67-406E-8BA2-23AE6F644B7A Q33259097-6266A99B-C144-432C-A5DB-F0A8D23B933D Q33325636-3705D822-645C-46FD-B5F9-E8F8A27C2EE8 Q33393949-6FD45E84-D9AA-4F17-982B-B806AFD33934 Q33582300-ADFE3A22-6B6C-4548-978B-456BF2931911 Q33756622-B50245A4-DCF3-4F72-AA9E-3A895EA40100 Q33783609-BC415805-8B39-4131-B4CC-3DB065A08B9C Q33785039-7928AA15-0AD3-453A-974F-10526641EA12 Q33820811-1B18BF96-CF2A-45DD-8C57-5000594C1D3C Q33841222-9295F594-2FC2-4CF2-9E35-A453DFE694F5 Q33869219-3C633B62-32FD-4780-B31B-D03C1408AE4A Q33939709-4A0EAD0F-F3DA-4549-B24E-1B0EEA6E44DD Q34095668-199DCC25-9910-4E28-B571-5D83A463AD72 Q34182555-91786516-B63D-4400-BB83-F9E7F4FC24D4 Q34248355-9B3E4352-41D9-493C-BCD7-FFEA6BE91B99 Q34482487-B98C942F-0D07-4226-8A1A-429414D82F73 Q34536425-1BD33FA0-9FE8-4C00-BB20-F6427F8AB966 Q34594769-63C7BAC0-AC1A-4A50-9212-F6FCF50F8950 Q34615086-0985A977-6662-4072-B4EA-51B50E8A64CF Q34691545-CD3A1E25-9AEC-4913-8686-BCA862495D4D Q35051712-7589CAA9-E131-4312-BB4B-13F565C5DE3E Q35073662-C634F373-3236-49BF-98F1-599DCBBE4149 Q35614635-6752FE16-A554-4D01-85B6-ED250CDAE30A Q35782660-C0AB3386-6442-43EF-BB09-5A4EC6EC05B7 Q35813115-E6BB6DA5-648E-4AA8-A8A0-97A0448FF66E Q35838039-1E290B71-FE13-4BDD-A7AD-63A300665772 Q35842135-4AB9F3C5-405C-4AEE-9F24-5BD98724E796 Q35843507-16EC500F-8056-4A28-A18B-6F9124C2BE47 Q35904413-30255FC3-09F1-4222-90A3-A17F90811873 Q35973425-950DB78D-7B2E-42E6-BD53-42CF89581466 Q36007167-A219753B-4306-453C-96A6-2F5EDC9A0214

P2860

Tumor-specific shared antigenic peptides recognized by human T cells.

http://www.wikidata.org/entity/Q35005926

description

2002 nî lūn-bûn

@nan

2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Tumor-specific shared antigenic peptides recognized by human T cells.

@ast

Tumor-specific shared antigenic peptides recognized by human T cells.

@en

type

label

Tumor-specific shared antigenic peptides recognized by human T cells.

@ast

Tumor-specific shared antigenic peptides recognized by human T cells.

@en

prefLabel

Tumor-specific shared antigenic peptides recognized by human T cells.

@ast

Tumor-specific shared antigenic peptides recognized by human T cells.

@en

P1433

Q35005926-CC342174-0208-4601-BCDC-16263BD5A3A8

P1476

Q35005926-0202B6BD-2836-42AC-A522-493E1FBF9550

P2093

Q35005926-0395D5A7-E5A1-4F5A-A33F-3C277937E237

Q35005926-09B47EAC-7647-4950-B826-AE7A3EDA0E72

Q35005926-16FE8E73-0B61-4B1B-883B-39EC9A5C3B7E

Q35005926-1786807F-BC4F-4749-BB01-12AE77809253

Q35005926-2C8799CC-9D82-471F-8337-06BB8409DA34

Q35005926-4DBC65F5-E318-48F5-9702-3CE695086D13

Q35005926-65F5808A-631F-4F58-900E-DA222D9D2680

Q35005926-9B9C782E-7A8E-498C-BCA2-FD6033CF2D31

Q35005926-D1389355-B3C2-41D2-B822-316A5280D168

Q35005926-E9ABBA04-773A-4DE5-90D3-401E2D70A569

P2860

Q35005926-05644642-638F-4FD4-A4FF-5391FBED199B

Q35005926-05A6AB30-FC20-4C32-9308-3CA5773117DD

Q35005926-08E8CE74-2137-46CA-93ED-58551779DB59

Q35005926-090C8DF3-D17E-46FB-B0C6-F185D5A7F803

Q35005926-106B6220-8C5B-4A91-8AE8-FD6F594FCC88

Q35005926-232A6068-BF5F-4499-8D88-FF6057F38A5F

Q35005926-24C21B12-5E51-4E80-9394-C6849FE062F3

Q35005926-25093CAB-6AD1-48C6-9EBB-5ED6E9F2B54B

Q35005926-288F6F5C-9408-488F-A250-D8C8E7F37121

Q35005926-2A063667-68CA-42E8-BB8C-1B9DE24EBB04

P304

Q35005926-6CD27F98-7267-47D7-83FD-E29ACEE89AEB

P31

Q35005926-4FF4400E-CEBE-45F1-9720-9AADD1BCF022

P356

Q35005926-E6E46427-DBD2-4CF2-82B1-55EFACFE2584

P478

Q35005926-1334AA6E-7F11-403A-A701-2EA305092D49

P577

Q35005926-258AE7E9-26A7-43AC-8D20-5C18F9985E5C

P698

Q35005926-9C1C6A66-AC85-49AD-ADE9-1E55AAE575C6

P356

J.1600-065X.2002.18806.X

P1433

Immunological Reviews

P1476

Tumor-specific shared antigenic peptides recognized by human T cells.

@en

P2093

Benoît J Van Den Eynde

http://www.w3.org/2001/XMLSchema#string

Christophe Panichelli

http://www.w3.org/2001/XMLSchema#string

Erwin S Schultz

http://www.w3.org/2001/XMLSchema#string

Francis Brasseur

http://www.w3.org/2001/XMLSchema#string

Jacques Chapiro

http://www.w3.org/2001/XMLSchema#string

Pascal Chaux

http://www.w3.org/2001/XMLSchema#string

Pierre Van Der Bruggen

http://www.w3.org/2001/XMLSchema#string

Thierry Boon

http://www.w3.org/2001/XMLSchema#string

Vincent Stroobant

http://www.w3.org/2001/XMLSchema#string

Yi Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens

Human tumor antigens recognized by T lymphocytes

A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes

Identification of a new, unorthodox member of the MAGE gene family

Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

LAGE-1, a new gene with tumor specificity

The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition.

P304

51-64

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1034/J.1600-065X.2002.18806.X

http://www.w3.org/2001/XMLSchema#string

P478

188

http://www.w3.org/2001/XMLSchema#string

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12445281

http://www.w3.org/2001/XMLSchema#string